Peregrine Pharmaceuticals (NASDAQ:PPHM) is a not yet profitable biotech based in Tustin, California. The company's pipeline consists of first-in-class monoclonal antibodies with a main focus on cancer treatment and imaging. Its three lead programs are in clinical trials for seven separate indications. Peregrine's wholly owned subsidiary, Avid Biosciences, generates enough revenue to partially offset the company's substantial clinical development costs.
Phosphatidylserine-targeting therapy, a new approach to fighting solid tumors
If you can remember your high school biology, you know that cell membranes are mainly composed of a phospholipid bilayer. The water soluble, or hydrophilic, "heads" of newly formed phospholipids face the inside of the cell with their hydrophobic "tails" pointed toward the center of the bilayer. Conversely, the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|